Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study

NCT07476807 | Enrolling By Invitation

• 1 other identifier: 1067SUHREC
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.

Conditions

Rash; Systemic Treatments; Tele-assessment

Outcome Measures

Primary Outcomes (1)

• time to clinical resolution

  Number of days from first AHOS contact to documented resolution (Grade 0-1).

  6 weeks

Secondary Outcomes (4)

• Escalation in person review

  6 weeks

• treatment modification reat

  6 weeks

• unscheduled acute contact

  6 weeks

• Patient-Reported Endpoints -Quality of Life (QoL) and patient satisfaction

  6 weeks

Study Arms (1)

Remote tele medicine assessment

OTHER

use of telemedicine

Other: telem healthassessment

Interventions

telem healthassessment OTHER

SOC is face to face assessment-this study aims to use telemedecine toassess Treatment related skin disorders

Remote tele medicine assessment

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT).
• New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT.
• Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria.
• Clinically stable condition not requiring urgent in-person evaluation.
• Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations.

You may not qualify if:

• Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria.
• Clinical status requiring urgent or immediate face-to-face medical assessment.
• Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects.
• Inability to access or effectively use the required telemedicine technology.

Sponsors & Collaborators

• Sligo General Hospital: lead

Study Sites (1)

Sligo university Hospital

Sligo, Sligo, f91h684, Ireland

Location

MeSH Terms

Conditions

Exanthema

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Research Nurse

Study Record Dates

• First Submitted: February 27, 2026
• First Posted: March 17, 2026
• Study Start: April 1, 2026
• Primary Completion: April 1, 2026
• Study Completion (Estimated): September 12, 2026
• Last Updated: April 28, 2026

Record last verified: 2026-04

Locations

IE (1)